Prior to that, he served as Executive Vice President and Chief Financial Officer of Endo International and as an executive in various global finance and strategy leadership roles at BD ( Becton, Dickinson and Company) including Interim Chief Financial Officer, Chief Accounting Officer and CFO of International. Upadhyay served as Senior Vice President, Global Financial Operations at Bristol Myers Squibb (BMS), where he was responsible for strategic and operational initiatives across BMS's supply chain, commercial operations, R&D and business development.
It is particularly exciting to join at such a pivotal time, when the company is in the process of transforming the treatment of multiple serious diseases, as it has done in cystic fibrosis,' said Suky Upadhyay. 'It's an honor to join Vertex, a company focused on serial innovation with an industry-leading track record of discovering, developing and commercializing transformative medicines to treat serious diseases. His extensive financial and strategic experience in health care, paired with his leadership and expertise across biopharma and medtech, make him a valuable addition to our board of directors,' said Reshma Kewalramani, M.D., Vertex's Chief Executive Officer and President. 'We are delighted to have Suky join the Vertex Board. He is currently the Executive Vice President and Chief Financial Officer of Zimmer Biomet, a leading global innovator and manufacturer of orthopedic solutions, a position he has held since July 2019. Upadhyay is a global business executive with more than 20 years of experience in the pharmaceutical and medical technology sectors, serving in financial and strategy roles covering multiple areas of the life sciences sector. BOSTON - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that Suketu ('Suky') Upadhyay has been elected to its board of directors as an independent director.
0 kommentar(er)
